Epilepsy. Epilepsy and recurrent seizures
Conditions
Interventions
Intervention 1: Intervention Pyridoxine, 40mg tablet (Darou pakhsh, Iran) once daily. Intervention 2: Control group: Placebo tablet with the same shape and color as pyridoxine, once daily.
Sponsors
Sari University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age >=18 years Patients affected by idiopathic generalized epilepsy Patients who are treated by levetiracetam (Levebel, Cobel darou) in recent month Complaint of behavioral problem Patient's consent for participation
Exclusion criteria
Exclusion criteria: History of known psychiatric disease Pregnancy Incidence of psychotic side effects including hallucination, psychosis, suicidal idea or attempt Treatment with psychiatric medications Alcohol or drug abuse Mental retardation to the degree that intervenes comprehension and response to questionnaire
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of pyridoxine in treatment of behavioral side effects. Timepoint: before intervention and 3 weeks after intervention. Method of measurement: Symptom checklist-90-revised (SCL-90-R) questionnaire.;Withdrawal rate of levetiracetam due to behavioral side effects. Timepoint: 3 weeks. Method of measurement: Patient interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNasim Tabrizi
Sari University of Medical Sciences
Outcome results
None listed